Alamar Biosciences launches a nationwide biomarker initiative with universities to analyze over 20k plasma samples for Alzheimer's research
Executive summary: Alamar Biosciences partnered with leading research universities to launch a national initiative that will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias participants using the NULISAseq™ Neuro 220 panel. The project generates a large blood‑based biomarker dataset that could advance early diagnosis, improve patient stratification for trials, and support future regulatory submissions for neurodegenerative disease diagnostics.
Who is involved: Alamar Biosciences, leading research universities (unspecified), and 10,000 ADRD participants contributing plasma samples.
Likely next: Completion of plasma sample profiling and subsequent data analysis to produce biomarker signatures, with results expected to be shared with the scientific community in the coming months.
Alamar Biosciences announced a partnership with leading research universities to profile approximately 21,000 plasma samples from 10,000 participants with Alzheimer’s Disease and Related Dementias using its NULISAseq™ Neuro 220 panel. The effort aims to create a large-scale blood-based biomarker dataset that could improve early detection and enrich clinical trials for neurodegenerative diseases. While the initiative is primarily research‑focused, successful validation of the panel may eventually translate into commercial diagnostic applications.
Timeline
- — Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases (GlobeNewswire)